28/10/2013 Thank you for your visit at FIE

We would like to thank you all for taking your time to visit our booth during FIE in Frankfurt.

It was a pleasure to meet you personally, giving us the great opportunity to show you our NEW PRODUCT: Slim-MED FORTE.

To download our brochure with complementary information,  click here

16/09/2013 Belgian health ingredients under the spotlight in Sao Paulo

With a population of some 200 million people, an increasing purchasing power, a strong and stable economy and a favorable political climate, Brazil has become a key market for companies around the world. For all of those reasons, the Wallonia Export & Investment agency defined Brazil as featured country for 2013.

From September 28 to 4 October 2013, an important economic mission will be held in Brazil. Belgian agro-food companies and their innovations will be highlighted. It is worth stressing that pharmaceutical and agro-food sector represents high potential markets in this country. This is an opportunity that KitoZyme cannot afford to miss.

KitoZyme is also pleased to invite you to participate in the Seminário Agroalimentar no Brasil “Ingredientes-Saúde e Alimentos Funcionais” taking place in the Hotel Tivoli on 1 October.

Please click here to arrange a meeting with our Sales & Marketing Manager, Mr. François Luthers and to discover the programme of the seminar.

13/08/2013 KitoZyme at Vitafoods Asia 2013

On September 4&5th 2013, KitoZyme will be present at Hong Kong. KitoZyme is currently looking for new partners in order to expand our fibers throughout Asia. KitoZyme will show you our: 

Strengthened by its European success, Slim-MEDTM wants to be deployed throughout Asia. This private label solution but also this branded finished product is awaiting for serious partners.

We hope to meet you at our booth #520 (BP05). 

Please click here to arrange a meeting with our team

25/06/2013 KitoZyme at IFT Food Expo

IFT Food Expo is the meeting point for players in global food sector. You'll find the industry's largest collection of food ingredients, equipment, processing, and packaging suppliers, all under one roof. It's the only place where the latest global food trends - and the products designed to meet them - are on display. More about this event here.

IFT Food Expo is the right place to present our natural, non-GMO, gluten-free and GRAS fibers.

We hope to meet you at our booth #752

Please click here to arrange a meeting with our team

29/05/2013 KitoZyme receives NBT Award at Vitafoods event

HERSTAL, Belgium – May 28, 2013 – Slim-MedTM received a prize trophy at the Nutraceutical Business & Technology (NBT) Awards gala dinner in Geneva, May 15.

Following two years of market-leading product development, Slim-MedTM is now recognized as the “Best New Finished Product” by a judging panel assembled exclusively from leading healthcare organizations and top business school academics.

Today there exists a real challenge for the Consumer Health industry as regards innovating within the weight management category. The major advance for KitoZyme with Slim-MedTM is the medical device statement which brings a strong technical file that incorporates both clinical evidence and safety. “To receive this award means a great deal for KitoZyme. It represents the clear recognition of the considerable efforts made by our entire team to find creative answers to the regulatory environment in Europe” explained François Luthers, Sales and Marketing Manager of KitoZyme.

Based on this challenge and the requirements of consumers, KitoZyme decided to pursue true innovation within the Consumer Health industry and to capitalize on the incredible functional properties of its proprietary fibers. “Right now, our goal is to provide two new products per year to our partners and to accelerate our growth by ensuring an innovation pipeline” concluded François Luthers.

The NBT Awards recognize and reward excellence in R&D, marketing, business and technology throughout the nutraceutical, functional food and beverage industry. The mission is to deliver a set of benchmarks to a global audience to achieve significant developments in terms of quality of service, health management, research, development and relationship management.

About Slim-MedTM

Slim-MedTM is a lipid binder to be used in the treatment and prevention of overweight in order to prevent diseases related to excess of weight and body fats. This private label, a class IIa medical device, is a unique business opportunity with product claims approved EU-wide. This medical device status guarantees a high level of quality and safety following the Directive 93/42. Based on a full dossier with clinical evidence and a guaranteed mechanism of action of vegetable chitosan, KitoZyme’s private label solution gains the approval of the authority.

If you want to know more about our medical device solution, click here


14/05/2013 KitoZyme at Vitafoods Europe

KitoZyme would be delighted to welcome you to our exhibition booth (number W05) at the Vitafoods Europe event that will be held in Geneva from 14-16 May 2013.

Visit our booth to discover our private labels to treat obesity as well as our specialty ingredients for arterial health, shelf life extension or weight and cholesterol management.

Furthermore, you will also be able to discover our new Slim-Med ™ for weight and cholesterol management as the NBT Awards finalist and in the New Product Zone.

Vitafoods Europe has become an essential event in the nutraceutical and food ingredients calender. A repution for showcasing many new products and giving visitors the opportunity to discover the latest developments in the industry, all at one time, in one place.

We hope to see you at our stand!

24/04/2013 KitoZyme and the University of Liège create SYNOLYNE

KitoZyme and the University of Liège create SYNOLYNE, a spin-off focused on arthrosis treatment

In collaboration with the University of Liège, KitoZyme, world leader in the production of vegetable chitosan, announces the launch of its first spin-out: Synolyne.

With a starting capital of about one million euros, Synolyne will focus on the research, development and marketing of a patented medical device designed to treat arthrosis by promoting cartilage repair.

Arthrosis is a joint disease. Its prevalence increases with age and the population’s increased life expectancy. It affects more than half the people aged over 65 and occupies the second rank of chronic diseases after cardiovascular conditions. It is treated by mouth or by intra-articular route, with paracetamol, hyaluronic acid, etc. According to a study by Frost & Sullivan conducted in the United States, the viscosupplementation market exceeded USD 400 million in 2010. The arthrotic joint supplementation biomaterial used by Synolyne will consist of a gel containing micropearls of KiOmedine-CsU®, an ultra pure chitosan of non-animal origin developed by KitoZyme  and produced using a patented process.

KitoZyme  received shares in the new company in exchange for its contribution in kind (an intellectual property licence agreement). The company will also receive royalties on future sales of Synolyne and will supply the biomaterial involved in the composition of the medical device, KiOmedine-CsU®.

In addition to KitoZyme  and the University of Liège (via Gesval, its valorisation interface), the shareholders in the new start-up are Meusinvest and Professor Henrotin, Director of the UROC (Unité de Recherche sur l’Os et le Cartilage, Bone and Cartilage Research Unit).

More about KiOmedine®

15/04/2013 KitoZyme at BIO Chicago

Meet us at CHICAGO - KitoZyme exhibits at the 2013 BIO International Convention 

KitoZyme will be exhibiting at the next BIO international Convention in Chicago during April 22-25, 2013.

We would like to invite you to visit our booth 2317 - Hall B and discover our KiOmedine® range of ultra-pure biopolymers for medical devices and drug delivery, together with a pioneering platform of innovative formulations.

Safe and reliable, KiOmedine® ultra-pure chitosan is ideal for:

  • Wound healing and hemostasis
  • Biosurgery
  • Scaffold and cell therapy
  • Drug delivery and vaccines

Partnering with KitoZyme and injecting KiOmedine® technology into your business will give you the competitive edge you need.

More about KiOmedine®

24/01/2013 Capital increase - 9 million EUR

KitoZyme - Capital increase - 9 million EUR

KitoZyme, an innovative company active in the biochemistry sector and a leader in its market segment, has announced the recent finalization of a capital increase for a total amount of 9 million euros.

The issue of new shares was reserved for and entirely underwritten by the company’s two main shareholders: the company Valois (Mestdagh Group and Montulet family) and the SRIW, the Wallonia Regional Investment Company.

This capital increase will significantly build the company’s equity and will allow it to actively continue developing new products and its international commercial expansion.

About us

08/01/2013 François Blondel joins KitoZyme as CEO

François Blondel joins KitoZyme as CEO

KitoZyme, the privately held Belgium-based world leader in the production of vegetable chitosan and chitin-glucan, is very pleased to announce the appointment of François Blondel as the new Chief Executive Officer of the company.

François Blondel, 49, was also appointed to the KitoZyme Board of Directors, effective November 30, 2012.

Prior to joining KitoZyme, François Blondel has gained broad experience in the management of innovation driven companies. He started his career in the chemical and in the oil and gas sectors, with assignments both in the United States and in Europe. In 1999, he joined International Brachytherapy (IBt), a startup in the medical device sector focused on cancer treatment. He served as CEO, leading IBt, a Euronext stock listed company, from its R&D stage to a successful and well diversified international group, European leader in its sector. Today, he is also serving as a board member of Compagnie du Bois Sauvage (diversified holding company listed on Euronext), Sopartec (holding of UCL university spinoffs), Nanocyl (world leader in production of carbon nanotubes), and a number of other companies active in the technology sector.

About us